Infection complications associated with the use of biologic agents

被引：79
作者：
Bresnihan, B [1 ]
Cunnane, G
机构：
[1] St Vincents Univ Hosp, Dept Rheumatol, Dublin 4, Ireland
[2] Univ Leeds, Dept Rheumatol, Leeds Gen Infirm, Old Nurses Home, Leeds LS1 3EX, W Yorkshire, England
来源：
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2003年 / 29卷 / 01期
关键词：
D O I：
10.1016/S0889-857X(02)00101-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The advent of biologic agents that target proinflammatory cytokines such as interleukin-1 (IL-1) or tumor necrosis factor alpha (TNFalpha) has revolutionized the understanding of the pathophysiology of inflammatory diseases and has given new hope to patients suffering from these disorders. Both IL-1 and TNFalpha play pivotal roles in inflammation and enhance the pathologic events in rheumatoid arthritis (RA) and other inflammatory arthropathies. Several clinical trials have evaluated a variety of therapeutic interventions that specifically block the effects of these biologic agents. Interleukin-1 receptor antagonist (IL-1Ra) has clinical, radiologic, and histologic benefits in patients with RA. Anti-TNFalpha agents such as infliximab, etanercept, and adalimumab are also efficacious in the management of inflammatory arthropathies.
引用
收藏
页码：185 / +
页数：19
相关论文
共 109 条
[41]   Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α [J].
Gorman, JD ;
Sack, KE ;
Davis, JC .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (18) :1349-1356
[42]  
Harriman G, 1999, ANN RHEUM DIS, V58, P61
[43]   INHIBITION OF INTERLEUKIN-1-INDUCED SYNOVITIS AND ARTICULAR-CARTILAGE PROTEOGLYCAN LOSS IN THE RABBIT KNEE BY RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST [J].
HENDERSON, B ;
THOMPSON, RC ;
HARDINGHAM, T ;
LEWTHWAITE, J .
CYTOKINE, 1991, 3 (03) :246-249
[44]   Etanercept in the treatment of adult patients with Still's disease [J].
Husni, ME ;
Maier, AL ;
Mease, PJ ;
Overman, SS ;
Fraser, P ;
Gravallese, EM ;
Weinblatt, ME .
ARTHRITIS AND RHEUMATISM, 2002, 46 (05) :1171-1176
[45]  
Jiang YB, 2000, ARTHRITIS RHEUM, V43, P1001, DOI 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO
[46]  
2-P
[47]  
KAVANAUGH A, 2002, ANN RHEUM DIS S1, V61, P168
[48]   Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].
Keane, J ;
Gershon, S ;
Wise, RP ;
Mirabile-Levens, E ;
Kasznica, J ;
Schwieterman, WD ;
Siegel, JN ;
Braun, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1098-1104
[49]   TRANSGENIC MICE EXPRESSING HUMAN TUMOR-NECROSIS-FACTOR - A PREDICTIVE GENETIC MODEL OF ARTHRITIS [J].
KEFFER, J ;
PROBERT, L ;
CAZLARIS, H ;
GEORGOPOULOS, S ;
KASLARIS, E ;
KIOUSSIS, D ;
KOLLIAS, G .
EMBO JOURNAL, 1991, 10 (13) :4025-4031
[50]  
Kempeni J, 1999, ANN RHEUM DIS, V58, P70
12345678910